Avalyn Adds Biopharma Veteran Jon Congleton to Board as It Preps Late-Stage Trials
Event summary
- Avalyn Pharma appointed Jon Congleton to its Board of Directors on April 6, 2026.
- Congleton currently serves as CEO and Board Member of Mineralys Therapeutics.
- He brings nearly 40 years of biopharmaceutical experience in cardiovascular, gastrointestinal, and CNS therapeutic areas.
- Avalyn is advancing Phase 2 programs MIST for AP01 and AURA for AP02.
The big picture
Avalyn's appointment of Jon Congleton underscores its focus on strengthening governance as it prepares for late-stage clinical trials. The move comes amid growing competition in the rare respiratory disease space, where targeted inhaled therapies are gaining traction. Congleton's background in commercial strategy and organizational leadership will be critical as Avalyn seeks to differentiate itself through better-tolerated treatments.
What we're watching
- Strategic Alignment
- How Congleton's experience in scaling biotech companies will shape Avalyn's transition to late-stage development.
- Clinical Momentum
- The pace at which Avalyn advances its Phase 2 programs MIST and AURA toward commercialization.
- Market Differentiation
- Whether Avalyn's inhaled formulations of pirfenidone and nintedanib can establish a new standard of care in pulmonary fibrosis.
Related topics